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 Crohn's disease is a chronic inflammatory bowel disease of 
unknown origin that continues to affect millions of people worldwide.  
Mycobacterium avium subsp. paratuberculosis (MAP) has been a 
suspected etiological agent of Crohn’s disease for nearly two decades.  
Recently, our laboratory was able to achieve a test sensitivity of 95.2% 
(n=21) by using a flow cytometry method (FCM) to detect anti-MAP 
antibodies in Johne’s diseased cattle.  Here we investigate whether FCM 
can differentiate Crohn’s patients’ antibody titers from healthy human 
control antibody levels.  As a second research goal, we investigated other 
suspected bacteria and serum-differentiating yeast using the FCM.  In 
brief, bacteria/yeast were incubated with serum samples and washed to 
remove nonspecific antibodies.  Antibodies bound to the surface of 
bacteria/yeast were then labeled with fluorescently-tagged secondary 
antibody and this binding evaluated by flow cytometry.  Serum samples 
from 37 Crohn’s patients and 37 healthy human controls were tested for 
antibody (IgG and IgA) binding to bacteria/yeast.  When targeting 
antibodies directed towards MAP, no significant difference was observed 
between the two populations (ANOVA, alpha=0.05).  FCM was also 
unable to detect an antibody response for either group when directed 
against a cell-wall-deficient form of MAP, which has been reported to be 
near infected tissues of Crohn’s diseased patients.  However, a differential 
antibody response to two yeasts that included S. cerevisiae and C. albicans 
was detected when looking for both IgG and IgA.  This differentiation 
using yeast agrees with previous studies that have shown Crohn’s diseased 
subjects to have significantly higher antibody titers to this yeast than do 
healthy controls.  This suggests that the flow cytometry method could be 
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CHAPTER I: SCOPE AND OBJECTIVES OF STUDY 
 
 Since its’ first description in the early 20th century Crohn’s disease (CD) 
has continued to confuse investigators and doctors alike, as the exact cause for 
CD has yet to be fully described.  Since 1984, when Mycobacterium avium subsp. 
paratuberculosis (MAP)  was first cultured from the inflamed intestinal tissue of 
three Crohn’s diseased patients [1], the possibility of there being a bacterial 
etiology for Crohn’s disease has been under intense scrutiny .  This question 
remains unresolved; however the plethora of research on the topic includes many 
findings that indicate MAP as an agent of CD.  It is of great importance to note 
that MAP is shed in the milk of dairy cows with Johne's disease (JD) and can 
survive the pasteurization process.  Thus, there is an immediate need to study the 
involvement of this potentially zoonotic bacterium in the pathogenesis of Crohn’s 
disease.  Yet, a consistently sensitive test for MAP is lacking even for JD-infected 
animals.    
 In 2005, our lab was able to differentiate populations of JD-infected and 
JD-negative dairy cattle using a novel detection method that utilized a Flow 
cytometer.  We obtained a sensitivity of 95%, which was considerably higher than 
commercially available diagnostic ELISAs that typically having sensitivities in 
the 15-30% range [2].  The method differs from these ELISAs in that it uses 
whole-cell MAP and therefore is able to detect antibodies directed against an 
array of MAP surface antigens.  Our primary objective in this study was to 
investigate the prevalence MAP-directed antibodies in Crohn’s diseased subjects 
and healthy controls.  We would utilize a similar technique to that used in the JD 
studies. Since MAP is not the only bacterial suspect to cause CD, we also 
investigated other bacteria as a secondary objective.  The method is universally 
designed to work for any bacteria and could be performed on any of these 
suspects.  Our third objective was to investigate antibodies directed to certain 
yeast species which have been known to improve the diagnostic prognosis of CD 
from other similar inflammatory bowel diseases.  If our method could increase the 
sensitivity of this test, those with unknown IBD could be more accurately 




CHAPTER II: BACKGROUND 
  
 General Information on Crohn’s Disease 
 
 An Introduction to Crohn’s Disease 
  
 Crohn’s disease (CD) is a chronic debilitating inflammatory bowel disease 
that affects millions of people each year. The disease is named for Dr. Burrill B. 
Crohn, one of three authors to first describe the disease in 1932 [3].  In America 
alone, the disease is believed to affect about a million individuals according to 
The Crohn’s and Colitis Foundation of America (CCFA) [4].  Interestingly, 
developed countries seemed to be more prone to high CD prevalences within their 
populations, but Western Europe and the United States seem to be particularly 
vulnerable [5].    
   Crohn’s Disease is a member of a broad group of inflammatory bowel 
diseases (IBDs) of unknown origin occurring in the gastrointestinal (GI) region.  
The similarities between CD and a second IBD called ulcerative colitis (UC) are 
striking and thus a differential diagnosis can often be difficult.  CD inflamed 
tissue regions can occur at nearly any region of the GI tract, but nearly 70% of 
those infected with CD will have granulomatous legions of inflamed tissue in the 
small intestine or the junction region of the cecum [6].  Diseased tissue is often 
described as cobblestoned with patches of healthy intestinal lumen often 
interrupting diseased portions [7].  Patients stricken with CD often experience 
bouts of stomach pain and have their lives severely affected by the 
unpredictability of their digestive system, a continuous malaise, and the 
coexisting malnutrition which often occurs.  Severe weight loss and diarrhea are 
common signs that CD may be setting in [7].   
 In about 50% of CD patients, inflammations can become severe enough to 
bring about a blockage (stenosis) that requires surgery [6]. The Crohn’s and 
Colitis Foundation of America estimates that, overtime, nearly two-thirds of CD 
patients will require a surgery to relieve a disease symptom.  One common 
surgery is the removal of blockages of the GI tract caused by extremely inflamed 
tissue [8].  Another is the removal of fistulas, which are regions of the intestine 
that have become connected with other, unintended organs and are leaking GI 
constituents to these organs [8].  An average of 25% of CD patients are expected 
to have such fistulas [8].  The bladder, the vagina, as well as other portions of the 
GI tract are commonly connected by such fistulas.  Internal bleeding within the 
intestines is a third disease severity which often calls for surgery.  About 5% of 
CD patients develop other more obscure symptoms like eye, skin, or joint 
inflammations due to CD onset [7].   
 Disease onset generally occurs in those 16-25 years of age but has also 
been seen to occur both in early childhood and late adulthood [9]. There is no 
standard method for diagnosing CD and a plethora of tools are generally used.  
The average wait time for specific diagnosis after presenting symptoms was 
recently reported to be 2 years [6].  Diagnostic approaches include X-ray 
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methods, endoscopy, biopsy, stool examination, and a family history check  [8].  
There is no cure for CD, only pharmaceuticals to relieve symptoms and severity 
of disease.  Of the many treatments available general immunosuppressants are 
used for severe cases of CD.  This is because immunosuppressants in the form of 
steroids tend to weaken the immune systems ability to fight other pathogens 
which is a dangerous venture.  Anti-inflammatories are very popular treatment 
choices for CD patients who have more moderate symptoms.  Antibiotics are also 
commonly administered to aide the downgraded immune system in fighting 
infections.     
  
 The Three Main Crohn’s Disease Etiological Theories 
  
 The name “Crohn’s disease” is often described as a misnomer as it may be 
better characterized as a syndrome, rather than a specific disease.  Disease often 
entails a single causative agent.  In CD, this etiological agent has yet to be fully 
proven [7].  Since its description in the 1930’s, a rigorous search for the root 
cause of CD has raged on.  To this end, three main theories have emerged.  The 
two noninfectious theories include an autoimmune theory and the genetic 
predisposition theory. 
 Since many other chronic inflammatory responses are considered to be 
autoimmune diseases (rheumatoid arthritis, diabetes mellitus type 1, etc) it is not 
hard to see why some have favored an autoimmune theory for CD.  This focuses 
on the overactive immune responses to what many consider to be self-antigens.  It 
is supported by evidence of manifestations of disease that are outside of the GI 
tract, such as the rheumatoid arthritis and other inflammations that can also occur 
with CD.  It is further supported by the extreme effectiveness of anti-
inflammatory agents which are effective on immune responses.    CD subjects 
have much higher titers of IL-12, IFN-γ, and TNF-α which are all hallmark 
cytokines of cell-mediated immune responses (TH1 responses) [5] Thus, many 
have proposed that CD too may be of similar autoimmune etiology.  That is, our 
own immune cells may be triggered to attack self-cells due to an over expression 
of certain inflammatory response cytokines.     
 The genetic predisposition theory seems to be gaining more ground as of 
recently.  Roughly 20% of CD patients have relatives that also carry the 
symptoms of CD  [7].  Twin studies show that at least 50% have of identical twins 
are simultaneously affected with CD [6].  In addition, particular ethnic groups 
(like the Jewish, Caucasian, and African-American communities) seem to be at a 
higher risk which also seems to indicate a common genetic link to acquisition [7].  
Lastly, certain mutations in particular chromosomes seem to indicate higher risk 
for disease.  Approximately 10-30% of CD patients have a mutated 
NOD2/CARD15 gene on chromosome 16 [7, 9].  This gene is thought to be 
expressed as a surface protein on human macrophages and monocytes as well as 
intestinal epithelial cells [9].  In particular, the protein may interact with bacteria 
and the antigens they express on their outer walls [7].  The protein is thought to 
control strong pro-inflammatory responses via the cell-mediated pathway, and 
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hence mutations may delay appropriate bacterial elimination responses.  One 
study by Hisamatsu et al. showed intestinal epithelial cells that expressed a 
mutant NOD2/CARD15 gene to be ineffective at removing a well known 
foodbourne pathogen, Salmonella typhimurium [10].   It is important to note that 
the NOD2/CARD15 data thus far elucidated are far from conclusive and up to 5% 
of the general population may have the mutation; most of which will not develop 
CD  [7].   
 The last of the theories is that of an infectious etiology.  This is the idea 
that a foreign biological entity is responsible for causing the chronic inflammatory 
disease.  Within the granulomas of the CD-infected tissues, numerous 
lymphocytes and macrophages conglomerate.  Such granulomas are witnessed in 
other infectious disease and hence, there is a strong suspicion that CD may 
involve a similar pathway.  There are a number of suspect microbial agents that 
are associated with this theory  [5].    
 
Non-MAP Microbial Suspects Postulated to Cause Crohn’s Disease 
  
An array of non-MAP bacterial suspects has been postulated to cause CD.  
A number of different methods have been employed to try and prove a bacterial 
association with CD.  Since a number have been postulated, this review highlights 
only the most convincing cases of bacterial suspects for CD.  These prominent 
suspects are listed in Figure 1 along with their reported prevalence upon 
publication.   
A study conducted by Liu et al. attempted to characterize the typical flora 
found in CD patients  [11].  The study examined tissue samples from CD patients.  
Primary antibodies against a select group of bacteria were used to detect bacteria 
presence.  Positive control tissues for each probed bacteria/virus were used to 
ensure the antibodies were specifically binding to the microorganisms.  The 
groups of tissues were diverse with some coming from Europe and others from 
North America.  Immunolabeling for 12 of the 16 CD tissue samples (75%) were 
positive for Listeria monocytogenes, , a bacteria responsible for a large percentage 
of food poisoning cases each year.  In contrast, none of the tissues from healthy 
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showed antibody binding to Listeria monocytogenes.  Most of the reactivity was 
observed within macrophages, indicating host cell invasion by the bacteria.  Yet, 
L. monocytogenes was also shown to coexist with two specific bacteria in 10 of 
the 12 tissues it was observed in.  It is, therefore, possible that L. monocytogenes 
was a secondary invader.  Further, another study conducted by Blaser et al. was 
unable to show increased antibody reactivity to the bacteria using the serum of 40 
CD subjects and 40 healthy subjects  [12]. 
The same study conducted by Liu et al. also showed a marked distinction 
in E. coli reaction with an overall positive reaction of 57% [11].  For E. coli 12 of 
the 21 CD tissues examined were positive for immunoreaction to E. coli antigens.  
Cartun et al. also found evidence of E. coli in 69% of formalin-fixed  CD tissue 
[13]. These findings agreed with Tabaqchali et. al who found a higher antibody 
titer to E. coli O antigens in CD subjects in comparison to healthy controls  [14]. 
Importantly, UC subjects also showed high antibody levels to E. coli antigens and 
thus, a secondary infection due to the chronic inflammation was not ruled out by 
these authors.    
Further, Liu et al. found a CD seroreactivity of 44% to the F group 
antigens of the genus Streptococcus  [11].  This finding was similar to Cartun et 
al. who found that 63% of their CD serum reacted strongly to the bacterial 
antigens [13].  Yet, 25% of UC subjects in the Liu study  also showed a positive 
immunoreactivity to these antigens indicating a lack in specificity for CD within 
the IBD group [11].   
In 1992, Weber et al. surveyed IBD patients’ stool samples and biopsies;  
including both CD and UC subjects [15].  Out of the 49 CD patients, 5 or 10.2% 
were positive for Clostridium difficile.  This was the most prevalent of the several 
microbes the investigators probed which also included MAP.  Yet, Keighly et al. 
provided evidence that C. difficile may not be involved when they  noted a 
spontaneous disappearance of the bacteria in CD patients’ stool when the study 
continued to follow a group which had previously tested positive for the bacteria 
[16].  Weber et al. also cultured a peculiar microbe well known for its role in food 
poisoning in Salmonella typhimurium from the stool of a UC patient [15]. 
Yersinia entercolitica had been postulated as a possible suspect for UC but 
not CD for years.  Yet a seven year study conducted by Saebo et al. involving 
1041 subjects are suggestive of some involvement of these bacteria for CD  [17].   
Of the 1041 subjects that were tested, only 41 of them tested positive for the 
bacteria via an agglutination test.  Of these, 3 of the 41 turned out to be CD 
positive or 7.3%.  While the prevalence rates are not as high as others that have 
been reported for CD, the unexpected finding that the bacteria was found in both 
UC and CD patients but not controls calls for further testing. 
Campylobacter jejuni also has raised suspicions lately, after being cultured 
by Weber et al. from the stool of a CD patient [15].  The common disease it is 
known to cause in humans, Campylobacter jejuni enterocolitis, was also found to 
share common host autoantibodies to UC and CD in a study conducted by 
Berberian et al.  [18].  This autoantibody directed against host red blood cells was 
found to be highest in CD serum, but the Campylobacter jejuni chronically 
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infected subjects also were found to produce the autoantibody in comparable 
amounts.   
Yersinia pseudotuberculosis and Yersinia enterocolitica can cause 
an acute terminal ileitis that can be a preceding symptom to Crohn’s 
disease  [19].   Others have shown elevated blood titers of the Yersinia 
genus in CD patients.   Homewood et al. discuss the evidence for this and 
conclude that the Yersinia correlation is likely due to secondary infections 
of the bacteria primed by Crohn’s like conditions.    
 
Yeasts and Their Importance in Diagnosing Crohn’s Disease  
 
A eukaryotic microbe that we are all familiar with in our daily lives has 
also been making an impact on the diagnosis of inflammatory bowel diseases.  
Yeast, both baker’s and brewer’s, is the common name for the eukaryote 
Saccharomyces cerevisiae.  For years food antigens were thought to play an 
important role in worsening IBD symptoms.  Main et al. reported the first known 
antibody response to a food antibody that was specific for CD but not UC [20].  
The authors probed a serum population of CD and HC for an antibody response to 
baker’s yeast.  A subsequent ELISA-like test utilized an isolated yeast antigen to 
elicit a response.  Serum populations included healthy controls, UC patients, and 
CD patients.  The results revealed an astoundingly strong response by CD sera 
with virtually no response at all by the remaining sera populations.  The marked 
differences are clearly visible in Figure 2.  Levels of antibody (IgG and IgA ) 
binding to S. cerevisiae in serum samples of CD patients were much higher than 
that in control and UC groups (Figure 1).   
The differentiation of the CD group from other groups was statistically 
more significant when IgA against S. cerevisia was detected. Since it is often 
difficult to distinguish between UC and CD, this test may offer an easy, virtually 
pain-free method of determining which IBD an individual may have incurred.  
Since the release of that study, a plethora of other papers differentiating sera 
populations based upon yeast antigens (usually called anti-S. cerevisiae antibodies 
or ASCAs) has peppered the scientific literature  [21].  Most of these consist of an 
ELISA format , with around 60% of the CD subjects showing an elevated 
antibody response to yeast.  Since only 10% of UC subjects show a similar high 
response, CD-UC differentiation is possible.  Further, a second differentiation is 
possible because only UC patients have been shown to produce autoantibodies 
against self-neutrophils (called atypical perinuclear anti-neutrophil cytoplasmic 
autoantibodies or p-ANCA).   The percentages detected using the p-ANCA assay 
are a virtual reciprocal of those mentioned with the yeast ELISA.  Thus, blood 
may be drawn and both assays can help give the gastroenterologist a good 
indicator of which disease may be present.  It is important to note, however, that 
there may be a difference in antibody production to yeast depending on one’s 
country of origin.  In one study conducted by Preda et al. only a low prevalence of 





























from Romania [22]. Another yeast, Candida albicans, has also been surveyed for 
its use as a disease marker for CD.  C. albicans has common surface antigens 
(notably a surface polysaccharide called mannan).  Thus in 2006, Standaert-Vitse 
et al. were able to show that C. albicans can act as animmunogen to the ASCA 
tests [23].  This is because it is able to mimic S. cerevisiae with its mannan-
protein production.  A second study conducted by Savage et al. showed a marked 
increase in antibody production to C. albicans in CD sera as compared with 
healthy controls [24].  Yet, it must be noted that an older study conducted by 
McKenzie et al. found no significant difference when they tested CD subjects and 
healthy controls for antibodies to C. albicans [25].   
Figure 2: Differentiation of serum populations based on IgG 





An Overview of the Case for MAP as an Etiological Agent of Crohn’s 
Disease 
  
 Presence of MAP or Antibodies Against MAP in CD patients 
 
Of all the microbial suspects touched on above, none has garnered as 
much attention as Mycobacterium avium subsp. paratuberculosis. The linkage 
between MAP and Crohn’s disease is one that has been long suspected, but 
received enormous attention after Chiodini et al. isolated an uncharacterized 
mycobacteria from the diseased intestinal tissue of three Crohn’s patients [1].  
DNA probes later revealed these mycobacteria to be MAP  [26].  Interestingly, 
many of the MAP particles which have been identified thriving in the intestinal 
regions of infected humans have taken on a cell-wall deficient form (spheroplast) 
[27].  This meant that the classical acid-fast staining used to identify mycobacteria 
is not able to differentiate these microbes  [28].  However, IS900 DNA probes are 
still able to detect the bacteria and one in situ hybridization study by Sechi et al. 
revealed that up to 70% of the Crohn’s patients tested positive for the MAP 
insertion sequence [29].  A follow-up study by the same group revealed that 
another 70% of CD patients were both positive for MAP by IS900 but, in 
addition, were also positive for the NOD2 mutation mentioned previously [30].  In 
2004 Naser et al. identified 46% of Crohn’s patients as having MAP DNA in the 
buffy coat of their blood while only 10% of the healthy controls were PCR 
positive [31].  Naser et. al was also able to culture MAP from the breast milk of 
two CD mothers, while none of the healthy controls cultivated bacteria [32]. 
It must be noted, however, that IS900 PCR methods aiming to detect MAP 
within Crohn’s patients have not always been as successful.  While some studies 
show IS900 PCR detection methods to detect the bacterium in up to 76% of 
Crohn’s patients, others have found prevalence rates that hover around 30-40% 
[33].  In addition, the some data revealed no significant difference between 
healthy controls and Crohn’s patients.   Such inconsistencies raise the possibility 
of cross-reactivity of IS900 PCR primer, with the most likely candidate being the 
insertion sequence derived from MAA.   
Mycobacteria-derived antigen p36 tests have provided further support for 
the MAP-Crohn’s connection.  Naser et al. found that this antigen reacted with 
86.5% of Crohn’s diseased patients and 89% of patients with leprosy or 
tuberculosis [34].  Conversely, only 10% of control subjects who had not received 
a BCG immunization tested positive.  These results broadly suggest 
mycobacterial involvement in CD acquisition [34]. 
It should be noted that, despite the similarities of CD and UC in their 
symptoms, UC-infected patients rarely test positive for MAP, showing that the 
presence of MAP is specific to CD.   A 2001 review by El-Zaatari et al. compiled 
recent research utilizing various detection methods including: direct culturing 
from diseased tissue, DNA hybridization, serological methods, and in situ 
hybridization[34].  All were able to detect MAP in CD patients with MAP 
 10
prevalence values ranging from 40% to 90% of CD patients tested.  On the 
contrary, UC patients rarely exhibited MAP presence with prevalence values 
ranging around 0% with only one DNA-DNA hybridization test result having an 
outlier 33% prevalence.  Non-IBD negative controls also tended towards zero 
prevalence rate with, again, the exception of the hybridization test which revealed 
a 17% prevalence of MAP [35].  Still, there exists the possibility that CD-infected 
tissues somehow provide a more lucrative environment for MAP to establish 
itself.  Therefore, mere presence of MAP within CD patients is not enough  to 
prove MAP causation.  This may be supported by the very mixed success rates of 
using anti-mycobacterial treatments reviewed by Chamberlain et al.  [28]. 
 
 Symptomatic Similarities Between CD and JD 
 
MAP is well-known as the causative agent of an intestinal chronic disease 
in ruminant animals, called Johne’s disease (JD), and symptomatic similarities 
between CD and JD have supported the hypothesis of an etiological role of MAP 
in CD.  Both diseases can result in a constant diarrhea and, in severe cases, can 
lead to lethal blood loss or anemia.  There are important similarities when one 
observes the inflamed tissue taken from diseased ruminants and humans as well.  
Granulomas are the main common feature to both tissue types.  CD- and JD-
infected tissues have goblet cells that are responsible for proper mucous secretion 
along infected areas [7].   Transmural inflammation, while rare in JD, is also a 
common feature of CD tissue samples [5]. In a 2004 review, Chacon et al. 
highlights the similarities in diseased tissues of UC, CD, JD seen in Figure 3 [5].   
However, there are some differences in symptoms of CD and JD as well.  JD-
infected tissues usually inflame the lamina propria while this is rarely seen in CD 
patients [5].  Another important distinction is the lack of fistulas, fissures, and 
pseudopolyps in JD-diseased tissue – these features are common in CD tissues.     
 
Since MAP has been studied intensively as a candidate causative 
agent of CD, details of MAP biology and MAP infection in animals, JD, 
are described below.    A complete understanding of the biology of the 
disease – and how it may make it through the food chain to our 
refrigerators – helps one to understand the significance of this bacteria as a 
zoonotical suspect. 
 
MAP General Characteristics 
 
MAP belongs to the genus Mycobacterium, which encompasses nearly 
100 species [5].  MAP bacilli resemble 1-2 micrometer long, plump rods when 
viewed microscopically [36].  Taxonomically, the Mycobacterium genus is most 
closely related to the genera Corynebacterium, Nocardia, Rhodococcus, and 
Streptomyces.  Microbiologists often characterize bacteria by the guanine-
























Figure 3:    Histology comparison between normal, UC, CD, and 
JD tissues (from Chacon et al [5])  
   
t MAP DNA has a characteristic G-C content of approximately 69% [37].   
 A defining trait of all Mycobacteria is their propensity for acid-fast 
staining.  Members of the Mycobacterium genus contain high concentrations of 
mycolic acid in their cell wall.  This component binds to the basic fuchsin dye 
used in the first step of the Ziehl-Neelsen Acid-fast staining procedure.  It does so 
when the carboxylic acid portion of the mycolic acid forms an ionic bond to one 
of the amine groups of the fuchsin [38].  This cell wall component is impermeable 
to the acid-alcohols used for decoloration.  The mycolic acid is also covalently 
bound to the peptidoglycan of the cell wall.  The cell wall of mycobacteria is 
covered further by capsular structure (also called outer layer) composed primarily 
of carbohydrates and proteins.   Further, the bacteria tend to produce a large 
amount of extracellular matrix which can be seen in a recent scanning electron 
microscopy image (Figure 4) taken by our laboratory in April of 2007.  
Extracellular pili resembeling those in the figure have recently been described by 
Alteri et al. in MAP’s close relative M. tuberculosis [39].  Further, the 
investigators revealed that MAP was found to carry the same gene responsible for 





































Amongst the Mycobacterium, there are two large groups; fast-growing and 
slow-growing.  Those in the latter group comprise most of the known pathogenic 
strains of the Mycobacterium genus, including  MAP, along with its infamous 
pathogenic relatives M. tuberculosis and M. leprea  [40].  These can be easily 
distinguished from fast-growers because slow growers only contain one set of 
rRNA genes, whereas fast growers contain two sets  [41].  Susceptible hosts vary 
considerably: MAA causes tuberculosis in birds, and opportunistic infections in 
immunocompromised humans.  Yet, MAA does not cause disease in cattle or 
other ruminants.  [42] 
MAP is one of three subspecies belonging to the mycobacterium species 
M. avium  [41] – the other two being Mycobacterium avium subsp. avium (MAA) 
and Mycobacterium avium subsp. silvaticum.  Of the three, MAP is the slowest 
growing with a generation time that can exceed 20 hours [5].  A recent genomic 
analysis between M. avium subsp. avium and MAP revealed greater than 97% 
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genomic similarity between the large genomic sequences chosen for the 
comparison [43].  Analysis of the dnaJ gene, a highly conserved heat shock 
protein used for phylogenetic analysis, revealed a 99% homology between the 
same two subspecies [44].  While the genetic and physiological make-up of these 
two seem to be related, the diseases and 
Recently, Li et al. used shotgun sequencing to determine that the entire 
genome of a laboratory strain of MAP, K10 was about 4.83 kbp long [37].  M. 
avium subsp. avium is substantially larger, with a genomic size of 5.48 kbp [5].  
The homology is such that the two subspecies probably differ by fewer than 75 
genes.  Lastly, many other mycobacterial species, including MAP’s closest 
relative MAA, have plasmid DNA in their genomic arsenal.  No such native 
plasmids have been found in MAP  [45].   
Two other key features distinguish MAP from related bacteria.  These are 
mycobactin J-dependence and the presence of a specific genetic insertion 
sequences [45].  Unlike all other known mycobacterial species MAP is a 
mycobactin auxotroph.  Mycobactins (lipid soluble iron chelators), along with the 
exochelins (water soluble iron chelators) are responsible for iron scavenging to 
ensure survival in iron-depleted environments.  Mycobactins contain a 
phenyloxazolidine ring while exochelins do not  [46].  In MAP and other 
mycobacterial species, both mycobactins and exochelins are necessary.  Since 
MAP lacks mycobactin J, it must utilize foreign, extracellular mycobactin J in 
iron-starved conditions.  This is why the bacterium was so difficult to culture.  
Twort was able to get around this because the M. phlei was providing the 
mycobactin J for MAP.   
A distinguishing feature of MAP is the presence of the insertion sequence 
IS900 [45].  This is a small, highly motile bit of genomic material which contains 
transposition-related genes.  Specifically, IS900 is a member of the IS110 family 
of insertion sequences [45]. It therefore lacks both the terminal inverted repeats 
and direct repeats expected in most transposable DNA.   Typically, 17-20 copies 
of these insertional sequences are found in MAP.  Other mycobacteria have 
similar, but distinct, insertion sequences.   As expected, MAA has the insertional 
sequence most closely resembling IS900.  Its version, IS1626, shares 82% 
homology with IS900 and is also in the IS110 family.  Yet we expect to find 
IS1626 in copies of three when probing MAA cells [45].     
Even within the MAP subspecies, significant variation is evident.  This 
seems to be related to where the MAP subspecies is isolated from.  Two major 
subspecies strain include the cattle (c strain) and the sheep (s strain) strains.  In 
reference to the only fully sequenced C strain (K10), a DNA microarray 
hybridization revealed significant deletions an S strain.  These deletions totaled 
approximately 30,000 base pairs which are about 0.6% of the genomic size of the 
reference C strain.  However, this test is only unidirectional and a second 
hybridization with a reference S strain must be conducted to ensure the deletions 
exist [47].  Lastly, it is important to note that there are subtle key differences 
within the IS900 sequence of MAP which allow us to determine our strain type  
[48].  We include further discussion of IS900 in the diagnostic methods section. 
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Johne’s Disease (JD), often referred to as ‘paratuberculosis’, caused by 
MAP,  is a chronic, often fatal enteric disease which mostly infects ruminant 
animals. In particular, it affects cattle and sheep -- the important economic 
cornerstones of many agricultural economies.  It is prevalent on every continent 
except Antarctica; in the United States prevalences reach as high as 85% on some 
farms [49].  Various characteristics of this microbe have made the eradication of 
Johne’s disease a very difficult prospect.  The economic implications of Johne’s 
disease can be quite severe and thus, a great deal of research has gone into JD.  
For example, it is now known that non-ruminants also harbor the acid-fast 
bacterium: in 1977, Matthews and Sargent isolated MAP from a brown hare [50].  
Such a vast host range represents an extremely tough obstacle for designing 
effective management techniques.  
 In general, animals are most susceptible to infection during the first few 
months of life [51].  While initial exposure occurs early, classical clinical 
conditions may take years to develop.  Transmission is believed to be primarily 
linked to oral ingestion of MAP-laden material.  Experimental infection models 
with adults have proven that disease resistance is acquired with age [8].  JD can 
be spread via direct and indirect contacts mechanisms. The most common means 
for direct transmission is through an infected mother’s milk or colostrum (first 
milk after calf delivery)  [51].   
Indirect transmission occurs most commonly via MAP-contaminated food 
or water sources.  Teats contaminated by fecal material can also cause oral-fecal 
transmission [51].  The minimal infective dose of MAP appears to be 103  bacilli  
[52].  Infected animals with clinical symptoms shed 106 to 108 MAP per gram of 
fecal material [52].    Thus, just a small amount of fecal contamination will go a 
long way in spreading disease.  To make matters worse, the onset of fecal 
shedding of MAP by infected cattle is nearly impossible to predict.   
Once infection is initiated, JD is mostly undetectable for the first couple 
years.  Thus, the disease spends much of its time in a subclinical phase [51].  Only 
5-10% of the subclinically infected animals will progress to more overt 
symptoms[51].  A late subclinical phase is marked by heavy bacterial shedding 
with no overt symptoms prevalent  [53].  Clinically infected animals shed high 
numbers of bacteria in their feces, rapidly lose weight, and exhibit low milk 
production.   Symptomatic animals will eventually die due to malnutrition.   
MAP’s ubiquitous distribution in the environment makes it impractical to 
eliminate the bacteria from a suspected farm.  Once infected, chemotherapeutical 
agents may be employed which will may reduce the severity of disease and in turn 
increase survival time.  However, no chemotherapeutic agent has been found that 
will completely relieve all symptoms and guarantee relapse prevention.  Vaccines 
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represent a second form of protection.  Yet, there have been only a few successful 
demonstrations of both live and killed bacteria vaccinations  [54].   
 
Survival of MAP in environment and milk 
  
 As mentioned earlier, MAP bacilli are surrounded by multiple layers, 
including cell membrane, cell wall, capsular structure and extracellular matrix, 
and are known to be extremely resistant to various chemical and physical 
treatments.  Consequently, MAP can survive in environments (e.g. soil and water) 
and food matrices (e.g. milk) for a relatively long term with maintaining their 
infectivity.  Since the majority of MAP transmission occurs through the oral 
route, contaminated materials are likely to cause the spread of MAP infections in 
animals and possibly in humans.  If MAP is a causative agent or deteriorating 
factor of CD, survival of MAP in drinking water and milk will be a food safety 
concern especially in countries where JD prevalence is known to be high.  
  
 MAP’s Physical Resilience In Vitro 
 
MAP is an extremely durable organism.  In the lab, it is able to resist high 
temperatures better than any of its closely related family members including M. 
avium subsp. avium, M. phlei, M. scrofulaceum, and M. xenopi.  Normal doses of 
UV light are adequately capable of killing the organism, yet the organism is 
slightly more capable of surviving sunlight than M. bovis.  Slight differences in 
overall pH in the 5-8 range have no effect on MAP’s survival.  Like MAA, 
chlorine has been showed to have a less pronounced effect on MAP survivability 
when compared to most other bacteria.   
 
 MAP’s Environmental Resilience 
 
 With such an enduring nature under laboratory conditions it is hardly 
surprising that this mycobacterium has also proven to be hearty in various 
environmental sampling experiments.  The bacterium remains extremely viable 
under various environmental conditions.  For instance it has been cultured after 
163 days in river water, 270 days in pond water, and 11 months in cattle feces 
[55].  Low temperatures can also be tolerated, as it has been cultured @ 14 
degrees Celsius for at least a year [55].    
 
 MAP’s Survival of Pasteurization Process 
 
 If MAP does cause a zoonotic disease in humans, its survival within 
commercially available dairy products would represent a very serious risk.    The 
mycobacterium has been isolated from both pasteurized and unpasteurized milk of 
infected dairy cattle.  Pasteurization is a process which was designed to eliminate 
possible bacteria (namely Mycobacterium bovis the etiological agent of 
tuberculosis) or other biologically active entities that can be found in collected 
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milk. The mycobacterium is found in milk by either direct secretion from the 
udder or a contamination of the udder by MAP-laden fecal matter.  While milk 
shedding is less prevalent than fecal shedding, it has been shown that about 30% 
of heavily infected animals will shed the bacteria in their milk[55].  While most 
studies have found low MAP counts from milk, shortcomings in current 
methodology prevent us from knowing the true viable MAP count in milk.  The 
processes used to rid the milk of faster growing organisms, are also harmful for 
MAP.  Secondly, fecal-contaminated milk enumeration methods have yet to be 
undertaken  [36].     
Different methods exist for milk pasteurization.  Mainly these consist of 
holder pasteurization and high temperature, short time pasteurization.  Holder 
pasteurization entails heating the milk to 63 degrees Celsius for an extended 30-
minute period.    High temperature, short time pasteurization involves a higher 
temperature of 72 degrees Celsius for just 15 seconds.  Several studies have been 
conducted using experimentally inoculated milk samples which were 
subsequently pasteurized using both methods.  Both methods were proven unable 
to completely rid the milk of viable MAP.    In addition, minimal starting 
concentrations of MAP in the milk are important if we are to seriously consider 
the possibility of MAP transmission through commercially available milk.  It has 
been shown that if milk is present at levels as low as 100 cuff/ml (colony-forming 
units per milliliter) some MAP survival is plausible under high-temperature, 
short-time pasteurization  [36].   Thus, cows with at least this concentration of 
viable MAP in their milk could be considered a public health risk; at least until 







 Most of the information garnered thus far on MAP detection has been 
acquired using animals affected with JD.  Since this is the only disease MAP has 
been proven to cause, this is hardly surprising.  Thus,  this section focuses on 
MAP detection techniques that have been developed for JD, but which might also 
allow us to look for MAP in CD patients to help evaluate the putative connection 
between the two.   
 
Detecting MAP in an Infected Host 
 
The jury is still out as to which diagnostic method should be utilized in 
accurately assessing one’s MAP infection status.  Since the disease has only been 
proven to cause Johne’s disease, most studies concentrating on finding direct or 
indirect evidence of disease have concentrated on its known animal hosts.  
Disagreement between labs using the same methods are common in the literature.  
There are many reasons why this may be true, including strain differences, the 
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slow-growth of MAP, and the heartiness of the bacteria to name a few.  Two 
important facets of any diagnostic method are its intrinsic sensitivity and 
specificity values.  These statistical terms are straightforward in their meanings.  
Sensitivity refers to a tests ability to detect all true positives.  Its value is only 
lowered by false-negatives.  Specificity refers to a tests ability to accurately assess 
the true negatives for a disease.  High combined specificities and sensitivities 
indicate that the test is both able to detect disease and differentiate the healthy 
from the infected.  Early detection of Johne’s via serological or non-serological 
methods remains a difficult task.  Thus while high specificities may be possible 
due to the low prevalence of false-positives, true negatives may be much less 
prominent.  This is because an infected animal may take months to years to 
progress to a disease state where detection is even possible due to the pathology 
of MAP.  The following discussion represents a synthesis of the newest research 
conducted and tries to gather some of the general sensitivity and specificity trends 




 Though there may be some who disagree, most researchers familiar with 
the diagnostic aspects of Johne’s disease would consider the fecal culture test the 
gold standard by which all other tests are usually compared against.   Though it 
has taken many years since fecal culturing began, today we are able to detect the 
presence of the bacteria both earlier and at lower initial prevalence. However, 
many questions still exist as to whether or not fecal culturing should be assumed 
to be the gold standard for infection status.  The bacteria can be extremely 
difficult to free from the fecal matter, and for this reason many low-shedding 
hosts may be misdiagnosed as being fecal culture negative.  In addition, since the 
mycobacteria are often consumed via contaminated feed or milk, there is a 
possibility that some fecal positive cultures are the result of these bacteria simply 
being processed and excreted with the ingested material.   
 Thus, there is the risk that the bacteria could be detected without ever 
establishing an infection. Cultures testing positive in this manner are said to be 
‘pass-through’ positives  [56].   Other problems with fecal culturing are the 
considerable efforts which must be expended to determine a given samples 
disease status.  The filtration and decontamination stages can be completed in 3 
days by the Whitlock method  [57], however even with sophisticated growth 
detectors, some cultures may take up to 60 days until microbial growth becomes 
evident  [57].  With such prolonged incubation times, laboratory costs can be very 
high.   
Despite these drawbacks, fecal culturing still represents one of the only 
direct methods to detect MAP.  Consequently, many still rely upon fecal culturing 
to obtain a cow or herd’s disease status when looking for Johne’s diseased 
animals.  While fecal culturing has become the standard for detecting MAP within 
the Johne’s disease animal hosts, the method has yet to be found useful in any 
Crohn’s disease studies.  However, as previously mentioned, there have been 
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several accounts of culturing MAP from various tissues and non-fecal fluids of 
CD subjects [1, 31]. 
 
Serological Methods: An Introduction 
 
Blood can be physically separated into different components of which the 
main constituents are plasma (the liquid portion) and red blood cells (the solid 
portion).  These can be obtained by simple centrifugation.  Plasma has many 
proteins associated with clotting called clotting factors which can be removed 
immobilized with special coagulants.  Once these clotting factors have been 
removed serum is what remains.  The sera contains antibodies and complement 
proteins.  In addition, other proteins exist within the serum that act as chemical 
signalers (cytokines) for different components of the innate and adaptive immune 
responses.    
Thus, it is clear that serum can provide us with a wealth of information 
about a particular organism’s immune responses.  Because we cannot readily 
detect the actual invasive organisms within the serum of an animal, serological 
testing remains an indirect, but very effective detection method.  Many different 
serological testing techniques have been developed to detect different aspects of 
the host organisms’ immune system.   
 
Humoral Immune Responses  
 
 The humoral immune response is directed by a strong TH 2 response.  That 
is, type 2 helper T-cells activated by the antigens direct B lymphocytes to mature 
into antibody secreting plasma B cells.  The antigen-specific antibodies may then 
bind to the surface antigen of free bacteria and mark the bacteria for eventual 
destruction via one of a number of available pathways including opsonization and 
complement killing.  Antibodies to a common antigen may exist in a variety of 
isotypes.  A variety of isotypes exist to allow the antibodies to capture antigen in 
multiple ways.  These may be produced by the same TH 2-activated B lymphocyte 
[38].    IgG is structurally very simple and is generally the most prevalent 
antibody circulating in tissue and blood of animals [58].    
For years,  the humoral immune response was thought to take a significant 
amount of time to develop in a typical paratuberculosis infection [59].  Thus it 
was considered by many to be an immune response dominating the later, clinical 
stages of MAP infection.  One major reason for this is that the enzyme-linked 
immunosorbant assays (ELISAs) often used to detect antibodies to MAP antigens 
are mostly seropositive after the animal has been shown to be shedding bacteria 
via fecal culturing.  Yet, recent work by Koets et al. challenges many of these 
assumptions  [60].  An advanced knowledge of the immunology concerning MAP 
infection will likely improve humoral immunity detection methods.  We will now 
discuss some of the common methods used to detect MAP-targeting antibodies.   
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AGID and CF Tests 
 
There are agar gel immunodiffusion (AGID) and complement fixation 
(CF) tests for the presence of antibody to MAP antigens.  Developed prior to the 
more sophisticated ELISA, these two assays offer an easy, quick visual 
affirmation of antibody presence. Both tests are fairly specific, but lack the 
sensitivity achieved by most ELISAs in cattle, goats, and sheep [61-63].      
AGID tests are extremely simple as they require only MAP antigen, the 
serum to be tested, and a known positive control.  Test results are available in two 
days [64].  The three constituents are placed equidistant from each other and 
injected into an agar gel.  If the antibodies to the antigen are present in the serum, 
the two will bind to form a precipitant.  A precipitant describes an insoluble 
complex formed from a soluble antigen and antibody [38].  This line should be 
compared to precipitant line from the positive control.  The Johne’s Information 
Center recommends that this test only be conducted on animals which have been 
clinically diagnosed due to their malnourished appearance or constant diarrhea 
[64].  There are no records of AGID testing with CD subjects.   
 The CF test utilizes an indirect indicator system to portray antibody 
presence.  The presence of antigen binding antibody is indicated by adding 
complement proteins.  Complement proteins exist as a part of our immune 
response to trigger a cascading effect of activating proteins which lead to effective 
clearing of pathogenic cells by creating holes in their cell membranes  [65].  
Complement proteins can be activated by a variety of different pathways.   
The classical pathway exists as an antibody-activated pathway [38].  The 
test works in the following manner; if the antibody is present within the serum, it 
will bind both the antigen and activate or “fix” the complement protein.  A second 
indicatory antibody is added which leads to sheep red blood cell lysis upon 
complement binding.  If all of the complement is already bound to the antibodies 
against MAP antigen, there will be a drop off in complement available to bind the 
anti-sheep RBC antibody.  Therefore, when we add sheep red blood cells 
hemolysis will occur to a lesser degree and the lawn of red blood cells will remain 
intact.  This would appear in the test well as a solid red lawn. 
However, if there is no antibody binding to MAP antigen, the inactivated 
complement proteins will be more freely available to bind to the anti-sheep RBC 
antibodies.  This will activate the classical complement system to eventually lead 
to hemolysis.  This would appear as a white or pink lawn in the test.  There have 




The enzyme-linked immunosorbant assay or ELISA has become the 
preferred method of antibody detection since its development by Yokomizo et al. 
in 1983  [66].   The ELISA is the preferred immunoglobulin detection method 
because it requires the least amount of antibody required to give a positive 
reaction [38].  It is also relatively cheap, and easier to standardize making 
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duplication easier [64].  Lastly, it is important to note that specificity of the 
ELISA significantly improved when M. phlei-absorbed ELISAs were introduced 
to reduce non-specific antibody binding and hence, false positives  [67].   
The ELISA for JD works by having some MAP antigens attached the 
wells of a ELISA plate [38].  Serum at a specific dilution is then added to the 
wells and allowed proper incubation time for the reaction between antigen and 
antibody to occur.  The wells are then washed to remove any materials that did 
not bind to the antigen.  A secondary enzyme-conjugated antibody specific for the 
animal and isotype of your targeted antibody is then pipetted into the wells.  After 
a second incubation the substrate for the enzyme is added to the wells.  If there is 
any antibody present for the targeted antigen, the secondary antibody with its 
conjugated enzyme will also be present and reacts with the substrate producing a 
coloration of the solution in the well.  The coloration of each individual well is 
directly proportional to the amount of antibody present.  These are read on an 
ELISA plate reader which quantifies the optical density or OD [38].   
Like IFN-γ, a number of different antigens have been used with ELISAs.  
This includes LAM proteins, heat-shock proteins, whole-cell MAP, ethanol 
extracted antigen, antigen 85, antigen 35, and antigens removed by whole-cell 
sonication techniques [60, 68-71].  In addition, different methods for antibody 
detection have been tried.  This has been mostly dominated by the extremely 
popular ELISA.  Thus far, very few ELISAs have been able to separate the 
populations with much effectiveness (See table 1-1).   Yet, there is hope with the 
ethanol-ELISA, the formaldehyde-treated ELISA, and the p35 ELISA having 
sensitivities in the 85-100% range  [69-71].   It must be noted, however, that 
whilst the p35 ELISA has shown a high sensitivity, it has a lower specificity  
(86.4%) than either of the other two aforementioned ELISAs which approach 
100% [69-71].   
ELISAs have been the most popular method for testing CD patients for 
MAP-directed antibody production.  Kreuzpaintner et al. used their own ELISA 
that utilized 45/48 doublet antigens shared between M. tuberculosis and MAP 
[72].  Bernstein et al. used a commercial ELISA to test seroreactivity between CD 
and HC groups [33].   
Using Flow Cytometry to Detect Bacteria 
 
An Introduction to Flow Cytometry 
 
Over the years, flow cytometry has proved to be an extremely useful tool 
in the medical and scientific community.    It has served as an extremely potent 
investigative tool for researchers wishing to address a wide array of biological 
questions.  These may include the monitoring of foreign or self-antigens, 
antibodies, chemokines, and key immunological markers.  Its applicability stems 
from the extreme sensitivity and specificity one is able to achieve with flow 
cytometry.   
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By its name the machine may seem deceptively simple.  Cytometry refers 
to the equipment for the characterization and measurement of cells and cellular 
constituents.  The ‘flow’ portion refers to how this cytometry is accomplished; by 
flowing a liquid stream containing the target of interest through an array of 
detectors.   This flow procedure allows for the subjects of interest to be lined up in 
the stream.  Once these targets are lined up, they pass through a laser beam and 
florescence emitted from or light scattered by the targets be captured by a 
detector.    The flow rate through the stream is controlled and constant, thus only 
the particles size affects how long the laser is kept from hitting its detector.  
Intensity of the fluorescent and light is converted into voltage, amplified and 
digitally recorded.    
Thus flow cytometry is both quantitative (frequency) and qualitative 
(size). This beam breakage between a source and a detector is called “forward 
scatter”.  In addition, secondary detectors will be set up to observe where the 
beams which encounter the particle are deflected.  This deflection is called “side 
scatter” and is observed by side scatter detectors (usually oriented about 90 
degrees to the laser).  While forward scatter mostly measures cell surface area or 
general size, side scatter can give good approximations of how a cell is deflecting 
light.  This deflection pattern is a qualitative property that details cell topography 
and can even give hints as to intra-cellular structure.  A cell with a rough surface 
is not going to deflect light in as ordered of a manner as a nearly perfectly smooth 
sphere bead.  It is important to note that both side-scatter and forward scatter can 
be utilized to estimate particle size [73] .   
In both cases, computers allow these measurements to be recorded and as 
many as 3 x 105  measurements can be made in a single minute  [73].  In addition 
to size and frequency recordings, most flow cytometers will have the ability to 
excite a fluorescent marker that may be attached to the target of interest.  
Secondary detectors will detect this fluorescence as it occurs and store it 
alongside the particle size information.  In this manner, the flow can be extremely 
specific.  Fluorescent monoclonal antibodies can be made which only bind to very 
specific epitopes.  If they are not bound, no fluorescence can occur and although a 
false positive may have a similar sized particle, it is nearly impossible that it will 
also contain the same epitope.  Another crucial aspect of modern day flow 
cytometry is the ability to make several simultaneous readings upon a single cell.  
For instance, if one wants to measure the expression of antigens A, B, C, D within 
a given population of cells, it would be possible to measure these for both the 
individual cells and within the population as a whole, as well.  A diagram of a 































Figure 5:  General schematic of flow cytometer courtesy of 












A Brief History of FCM Development Towards Studying 
Microbes:   
 
Though it has its conceptual origins under Moldovan as early as the 1934, 
it was not until the 1950’s -- with the advent of a detector developed by Coulter 
that could differentiate cell volumes [73] - that flow cytometry (FC) began to 
make significant progress.  These early flow cytometers were equipped with  
“Coulter Counters” that used the differences in electrical signal absorption from 
their media to determine approximate volumes [74].  Optical means of cell 
volume differentiation later replaced the Coulter Counters due to their superiority 
in many different aspects of cell volume differentiation.  Cell sorters were a 
second important milestone in the evolution of the flow cytometer.  This feat was 
achieved by Fulwyler who was able to successfully sort human and mouse red 
blood cells based on differences in their total cell volume [75].  This apparatus 
would allow the investigator to single out only the cells of interest to be studied 
and eliminated an enormous amount of possible background noise.   
Improvements in optical technologies and fluorescent markers allowed 
researchers to begin investigating the microbial world using flow cytometry 
around the1970’s  [74].  In an important early experiment, Hutter and Eipel were 
able to observe previously undetectable microbial entities.   Various measurement 
parameters including, protein content, DNA content, and chlorophyll content were 
measured from a diverse group of microorganisms that included some yeasts (S. 
cerevisiae) , a prokaryote (E. coli), and some filamentous fungi [76].    This work 
was conducted using a flow cytometer developed primarily for working with 
larger, mammalian cells.  A necessary final step had to be taken in order for flow 
cytometry to be of use for microbiologists: bacteria and similarly small particles 
needed to be studied using instruments that had a high signal to noise ratio.  This 
meant eliminating background noise.   
In 1979, Steen and Lindmo addressed this issue by redesigning the chamber 
through which the fluid and laser interact  [77].  They aimed for the fluid to flow 
over a glass cover slip in an ordered manner which created a laminar flow  [77].  
This cut down on background noise and allowed for a high enough sensitivity to 
detect smaller prokaryotes.   There was a catch, however, because these flow 
cytometers utilized arc lamps instead of lasers.  With arc lamp flow cytometers, 
multi-parameter flow cytometry of more than two fluorescent parameters is not 
possible [74].  Cell sorting is also not an option with arc lamp models.  With time, 
further improvements in laser and computer technology allowed the laser-based 
flow cytometers to become sensitive enough to detect the smallest bacteria.  Even 
smaller biological materials, such as DNA, can now be observed.  Armed with 
these more precise instruments, research on bacteria using FCM has become 
much more prevalent as evidenced in Figure 6 by Davey et al. in their review of 






























Figure 6:  Graph displaying increasing flow cytometry 
papers concerning microbes during the period from 1980-
1996.  Davey et al. did a database search on two criteria: for 
any paper concerning flow cytometry (open circles) and for 
any papers containing both the words ‘flow cytometry’ and 
‘bacteria’ (solid circles).  The percentage of flow cytometry 
papers dealing with bacteria were then mapped as a 
percentage of the total papers dealing with flow  cytometry in 










Fluorescent Staining in Flow Cytometry 
 
When an atom absorbs light energy, its electrons enter an excited state in 
which they may jump to a higher energy shell level.  When they return from this 
level to the normal, ground state a photon with a characteristic energy can be 
emitted.  This everyday phenomenon is termed “fluorescence” and it can be a 
valuable tool when optimized in flow cytometry.  Since fluorescence is always of 
lower energy than the light energy that initiated the phenomenon, the emitted 
fluorescent light may be detected and quantified  [74].  Different fluorescent dyes 
have characteristic extinction coefficients which dictate at what wavelengths of 
light a particular dye will absorb the maximum amount of light.  In addition, 
different fluorescent dyes emit at different wavelengths.  This makes possible 
multiparameter techniques not only using flow cytometry but also simple 
fluorescent dye microscopy.    
Fluorescent staining in flow cytometry allows us some very distinct 
experimental advantages  [73].  First, a fluorescent emission is directly 
proportional to the fluorescently-tagged biological materials.  Secondly, very low 
concentrations of any fluorescent dye may be detected, due to the possibility of 
multiple fluorescent emissions per passage through the beam.  This provides a 
general amplification of the signal and leads to greater overall sensitivity.  Lastly, 
non-fluorescent compounds can be altered by enzymes to allow for fluorescence.  
This allows us to saturate a sample and only detect those which have the 
appropriate enzymes.   
 Ideal dyes for flow cytometry have extinction coefficients which are 
highest at the corresponding wavelength energies of the lasers of the flow 
cytometer being used.  Other crucial properties include how many times a 
molecule can be excited before it breaks down,  what is the maximum energy a 
dye can withstand before it breaks down, the duration of fluorescence, and how 
sensitive it may be to its chemical environment  [74].   
Fluorescin isothiocyanate (FITC) is one of the most widely used 
fluorescent dyes in all of flow cytometry.  FITC has its maximum absorption 
wavelength at 490 nm.  This is ideal because most flow cytometers use a argon 
laser which has a blackbody radiation curve peaking at 488nm  [74].  FITC emits 
a photon with a characteristic peak at 520 nm and these photons are generally 
detected at sensors adjacent to the side-scattering detectors.  FITC also can exert 
multiple signals per molecule because it exerts its photon over a very short period 
of time of 4 nanoseconds [78].  Since the typical sample passing through a flow 
chamber contacts the laser for 10 to 100 microseconds, the detector will observe 
more than one signal from a tagged item and thus will be more sensitive to even 
trace amounts of FITC-tagged material.  Lastly, FITC also has a high quantum 
yield at biological pHs of 8 making detection optimal for typical biological assays 
[74].   
FITC can either be used in two important, but distinct manners.  First, 
researchers may use FITC to bind to all available proteins in a given sample [79].  
This allows access to a number of data collecting possibilities including the ability 
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to distinguish cell cycle status, differentiate different cell types based on overall 
protein expression, or any other investigation when the amount of protein per 
constituent may be of interest.  Secondly, more specific assays may be done by 
conjugating FITC with antibodies to bind only one particular antigen type  [73].  
Once these antibodies bind their target, the attached FITC will fluoresce when the 
complex passes through the argon laser.  Similarly, FITC secondary antibodies 
which bind to species-specific antibodies are commonly used. 
 
 
 Fluorescent-based FCM Method by Dietrich et al. 
 
Humoral responses to bacteria have been measured in a number of 
different ways, as discussed previously.  However, in 1991 Dietrich et al. outlined 
a method for detecting host immune responses to whole-cell bacteria using flow 
cytometry [80].   In this original study, the authors used a secondary antibody 
conjugated with FITC which targeted the F’ab regions of the bovine IgG 
antibody.   The study focused on a group of 18 cattle which were challenged with 
live B. abortus.  They sampled blood from the cattle at prechallenge, 1, 2, and 4 
weeks post-inoculation.  In the initial step of the assay, they incubated bovine 
serum with the B. abortus which was fresh from a culture.  After the incubation, 
nonspecific antibody binding the bacteria was prohibited by washing twice with 
PBS.  A second incubation with the FITC conjugated-anti bovine secondary 
antibody was performed.  Washes were performed after an incubation period and 
the bovine antibody binding to B. abortus was assessed using flow cytometry.  
The results of the study proved very promising:antibody titer increased from a 
near zero level as expected as the weeks progressed and the cattle’s immune 
systems began producing immunoglobulins to the challenge bacteria.  The study 
ended with exciting results as the authors proclaimed,  
 
“In summary, we have developed a fluorescence based flow cytometric assay to measure 
antibody binding to intact bacteria using blood samples as the source of antibodies.  The 
assay was as reproducible as the standard EIA (ELISA-immunoassay), it was easier to 
run and it produced data in a format that was more applicable to our research needs.  We 
are using this assay to measure specific antibodies in bovine plasma samples to B. 
abortus but the assay could be suited to the measurement of antibody to binding any 
bacteria.” 
 
Developing a FCM Method for MAP antibodies 
 
In 2005 our lab developed a similar flow method to detect antibody 
binding to MAP in sera of cattle on JD+/- dairy herds  [2].  Like the Johne’s 
ELISA, the Flow Cytometry Method (FCM) also uses a secondary antibody as an 
indicator of the presence of antibodies against MAP.  In principle, the idea is to 
incubate serum with whole-cell MAP to allow antibody to bind to the surface of 
bacilli.  Washes remove unbound materials and the bound host antibodies are then 
tagged using FITC-labeled secondary antibodies that are specific for bovine 




































Figure 7:  Schematic of the antibody binding 
complex that is detected by FCM 
composed of antigen, bound primary antibody from the serum, and bound labeled 
secondary antibody that is labeled with FITC for detection.   
The complex is then run through the flow cytometer to detect antibody 
binding by immunofluorescence.  When tested with other related mycobacterium, 
this study proved the assay to be specific for MAP antibodies.  The lab used 21 
serum samples from cows which had produced 2 or more positive fecal samples 
as the positive controls.  Serum samples from 30 cows which had been testing 
serum negative by ELISA for 20 years were used as the negative control and gave 
both the diagnostic specificity and cut-off value.  The mean fluorescence of this 
group was determined and the cut-off was set three standard deviations above 
mean negative fluorescence value.   Using this method, the assays’ sensitivity was 
estimated to be 95.2% with a specificity of 96.7%.  This differentiation is shown 




























Figure 8:  Differentiation of JD negative (1) 
and JD positive (2) cattle sera, based on 
FCM-derived S/P values (from Eda et al [2]) 
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CHAPTER III: Materials and Methods 
Serum Populations 
  
Serum samples from a total of 74 individuals were tested using the FCM ; 
37 were from known CD patients (the CD group - all volunteers) and 37 from 
healthy controls (the HC group).  All 37 CD patients came from our collaboration 
with M.D. of Gastroenterology, Dr. Anderson.  Dr. Anderson is assistant 
professor and Chief of the Gastroenterology Division at UT Medical Center. In 
April 2005 his patients were sent a letter asking them to participate in our study.  
The packages included a cover letter (Figure 9) and an agreement to the terms of 
the study (Figure 10).   The patients were directed to come to UT Medical center 
and have blood collected at their convenience.  Patients diagnosed CD by 
Dr. Anderson or any previous M.D. were considered to be truly positive for the 
assay purposes.  Any donated blood was collected by trained phlebotomist 
personnel and placed in BD Vacutainer © (BD bioscience, Franklin, New Jersey) 
serum collecting tubes.  The tubes were usually picked up and transported back to 
our lab for proper storage at -20ºC.  The samples were documented with names, 
ages, and gender.   
Healthy controls (HC) were obtained from three independent companies.   
Bioreclamation Inc provided us with 20 samples which were donated by those 
claiming to be CD-negative by questionnaire (Bioreclamation Inc. New York, 
NY).  Since CD-positive blood is more valuable and therefore the donor can 
receive more compensation, the questionnaire is rarely falsified when it comes to 
disease status. Seventeen other CD-negative samples came from Profile 
Diagnostics Inc. and were guaranteed to be CD-negative by questionnaire, as well 
(Profile Diagnostics Inc.  Sherman Oaks, CA). 
Once in the lab, aliquots of sera were made by first spinning down the BD 
vacutainer tubes and collecting the remaining supernatant.  Aliquots were 
subdivided into 2.5 ml master tubes, and smaller 600 µL tubes.  This was done to 
assure we had appropriate back-ups in case that a serum is contaminated with 
other sample or that antibodies in serum are inactivated by multiple freeze-thaw 
processes.   The larger volume, stocking tubes were kept in freezer at -80ºC.  The 
smaller tubes to be used directly in the experiments were kept at -20ºC for easier 
access and shorter thawing periods.  All CD-negative and CD-positive sera were 




I would like to invite you to participate in a study that is being conducted by Dr. CA 
Speer’s Laboratory at the University of Tennessee, Agriculture Campus.  Your 
participation requires a one time blood draw of 10-20 mls (a little more than a 
tablespoon) and a disclosure of your age and gender.  The blood will be drawn at UT 
medical center’s phlebotomy laboratory and the procedure should take less than 15 
minutes.  There will be no cost to you or your insurance company for the blood draw.  
As you are aware Crohn’s disease (CD) is currently diagnosed by a combination of 
tests, including blood/stool test, X-ray examination, colonoscopy and biopsy.  Since 
some of these tests are difficult, invasive and hard to interpret, there is a need for a 
simple and less-invasive test for the disease.  It has been shown by some investigators 
that most CD patients have serum antibodies against a bacterium, called 
Mycobacterium paratuberculosis, which may be involved in CD.  Dr. Speer’s Lab has 
developed a method to detect such antibodies with high sensitivity and specificity, and 
the method requires only a small amount of blood from patients with CD.  Further efforts 
on the development of a diagnostic test for CD based on the Speer Lab method would 
benefit CD patients by providing more accurate diagnosis and by reducing risk, cost, 
and time required for diagnosis.  
Mycobacterium paratuberculosis (MP) causes a disease similar to Crohn’s disease in 
cattle and other animals called Johne’s disease.  MP involvement in CD has also been 
indicated in a number of scientific studies but to date no conclusive evidence has been 
found.  However, recent studies showed that antibiotic treatments that are effective 
against MP resulted in long-term remission of CD, supporting the hypothesis that CD 
might be caused by mycobacteria.   The test for MP developed in Dr. Speer’s Lab is far 
more sensitive and specific for MP bacteria than anything that has been provided 
previously.   If these studies help prove that MP is involved in CD it may lead to new 
therapies for Crohn’s disease.   If you have questions about the Informed Consent 
Form or if you would like scientific literature or more information on MP please 
contact Cathy Scott at 865-974-0465 or mcscott@utk.edu.  
If you are willing to participate in the study please fill out, sign and take the 
enclosed Informed Consent and Dynacare forms to the University of Tennessee, 
Patient Service Center, POB (Physician Office Building Ste 155) and ask to have 
your blood drawn for the Speer Lab Study.  A copy of your Informed Consent Form 
will be mailed to you at the address you provide on the Dynacare form.  
Sincerely,
Dr. Mark Anderson M.D.
Figure 9:  Cover letter for Crohn’s volunteers 
 30
Detection of Mycobacteria paratuberculosis Antibodies in Crohn’s 
Patient Serum.
Dr. C.A. Speer Ph.D.                                            
Dr. Shigetoshi Eda Ph.D.                                                     
Forestry, Wildlife and Fisheries                                
University of Tennessee                                         
274 Ellington Plant Science                                     
Knoxville, Tn 37996
Dr. Mark Anderson M.D.                                          
1928 Alcoa Highway
Medical Office Building B, Suite 100
Knoxville,TN 37920
The study in which I am being asked to participate by your Gastroenterologist Dr. Mark 
Anderson has the goal of producing a quick and accurate test for Crohn’s Disease (CD).  
It has been shown by some investigators that most CD patients have serum antibodies 
against a bacterium, called Mycobacterium paratuberculosis, which may be involved in 
CD.  We have developed a method to detect such antibodies with high sensitivity and 
specificity, and the method requires only a one time blood draw of 5 to 10 mls from 
patients with CD.  UT medical center’s phlebotomy lab [University of Tennessee, Patient 
Service Center, POB (Physician Office Building Ste 155)]  will draw a little more than a 
tablespoon of your blood, the procedure should take less than 15 minutes, there is a 
possibility some redness or swelling could occur.  If redness and swelling do occur they 
will not last long. This is a preliminary study involving 20 to 40 subjects; if the initial 
findings are promising more Crohn’s patients will be enrolled.  Further efforts on the 
development of a diagnostic test for CD based on our method would benefit CD patients 
by possibly providing more accurate diagnosis and by reducing risk, cost, and time 
required for diagnosis.  
I have read the description of the study and I have freely volunteered to participate.  I 
understand that I do not have to take part in this study and that my refusal to participate 
will involve no penalty or loss of rights to which I am entitled and it will not adversely 
affect my subsequent medical care.  I have had an opportunity to ask questions of the 
doctor and have received acceptable answers.  I understand that I will receive the same 
treatment for my condition weather I participate in the study or chose not to participate.  
No treatment decision will be made from the results of the tests.  
There is no additional medical cost to me or my insurance involved for the test, all 
expenses will be paid for by Dr. Speer’s lab through The University of Tennessee, 
Institute of Agriculture.  My Blood will be drawn by Dynacare a UT contracted 
phlebotomy lab, Dr. Speer will not be involved in any medical procedure.     
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I understand that I am not waving any legal rights or releasing the hospital or its agents from 
liability for negligence.  I understand that in the event of physical injury resulting from the 
research procedure, The University of Tennessee does not have funds budgeted for 
compensation either for lost wages or for medical treatment.  There is no additional medical 
cost to me or my insurance involved for the test, all expenses will be paid for by Dr. Speer’s 
lab at the University of Tennessee, Institute of Agriculture.
PATIENT CONFIDENTIALITY
Although study results may be published, your confidentiality will be maintained. Your name 
or information identifying you will not be released without written permission unless required 
by law. Under federal privacy regulations, you have the right to determine who has access 
to your personal health information (called “protected health information” or PHI). PHI 
collected in this study may include your medical history, the results of physical exams, lab 
tests, x-ray exams, and other diagnostic and treatment procedures, as well as basic 
demographic information. By signing this consent form, you are authorizing the researchers 
at the University of Tennessee Medical Center to have access to your PHI collected in this 
study and to receive your PHI from, Dr. Mark Anderson M.D., and the University of 
Tennessee Medical Center where you have received health care. In addition, your PHI may 
be shared with other persons involved in the conduct or oversight of this research, including 
the (FDA) Food and Drug Administration, the University of Tennessee Medical Center, and 
the University of Tennessee Graduate School of Medicine Institutional Review Board. Your 
PHI will not be used or disclosed to any other person or entity, except as required by law, or 
for authorized oversight of this research study by other regulatory agencies, or for other 
research for which the use and disclosure of your PHI has been approved by the IRB. Your 
PHI will be used indefinitely. You may cancel this authorization in writing at any time by 
contacting the Principal Investigator listed on the first page of the consent form. If you 
cancel the authorization, continued use of your PHI is permitted if it was obtained before the 
cancellation and its use is necessary in completing the research. However, PHI collected 
after your cancellation may not be used in the study. If you refuse to provide this 
authorization, you will not be able to participate in the research study. If you cancel the 
authorization, then you will be withdrawn from the study. Finally, the federal regulations 
allow you to obtain access to your PHI collected or used in this study. However, in order to 
complete the research, your access to this PHI may be temporarily suspended while the 
research is in progress. When the study is completed, your right of access to this 
information will be reinstated. 
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Figure 10 continued 
If you have any questions regarding this study, you may contact the Co-Principal 
Investigators, Dr. C.A. Speer at 865-974-0467 or Dr. Shige Eda as well as the Study 
Coordinator Cathy Scott at 865-974-0465.   If you have any questions regarding your 
health or risks associated with participating in the study you may contact your physician 
Dr. Mark Anderson at 865-544-6570. If at any time you have any further questions about 
your rights as a participant in this research protocol, you may contact the University of 
Tennessee Graduate School of Medicine Institutional Review Board (a group of people 
who review the research to protect your rights) at 865-544-9781.  Thank you for your 
consideration.
You will receive a copy of this consent form for your records.
______________________________ _________________________
Signature of Subject Date 
______________________________ _________________________
Signature of Principal Investigator Date
.
Subject’s Age-___________________
Subject’s Gender- M or F
Dynacare- Draw two red top no additive vacutaner tubes of blood attach this form and 





   
Whole-cell MAP   
 
To culture MAP we used a Middlebrook broth that has become standard 
for many mycobacteria since its discovery by Middlebrook et al. during the 
1950’s [81, 82].  Specifically, Linda strain MAP (ATCC© 43015) was cultured in 
Middlebrook 7H9 medium (Becton Dickinson, Cockeysville, Maryland) with 
10% oleic acid, albumin, dextrose, and NaCl (OADC).  This particular strain was 
thought to be ideal for such a study as it had been originally isolated from the 
intestinal mucosa of a 15 year-old Crohn’s patient named Linda [1].   Interestingly, 
the strain was reactive to antibodies in sera obtained from JD-positive cattle in the 
FCM assay as well [2].  Since mycobactin J is critical for the growth of MAP, 2 
μg/ml of the iron chelator was added to the growth media [45].  Media were 
prepared aseptically, with autoclaving for the M7H9/mycobactin J solution and 
vacuum filtration for the OADC due to denaturing concerns under high 
temperature conditions.   In our previous work, we found that MAP bacilli were 
not antigenic until they had been growing in media for at least 3 months.  This 
may be due to the slow-growing nature of MAP.  Visible films of bacteria along 
the bottommost region of the flask were a good visual indicator for proper growth 
state.  Periodic culture antigenicity assays were conducted to identify those 
cultures which exhibited the strongest antibody reactivity to pooled samples of 
JD-positive serum.  Those with strong fluorescence using a JD-positive, and weak 
to negligible fluorescence using the JD-negative pooled sera were chosen as 
positive and negative controls for testing serum samples corrected from CD 
patients.     
MAP Spheroplasts 
Spheroplasts or cell wall deficient (CWD) forms of MAP have been 
isolated from CD patients, so it was important to examine if CWD forms of MAP 
can be used to detect anti-MAP antibodies in CD patients  [27].  In 2003, Hines et 
al. successfully transformed a strain of MAP with a full cell wall to a CWD form 
of MAP [83].  We, therefore, prepared CWD form of MAP (Linda strain) 
according to their protocol with minor modifications.  First we spun down 10 ml 
of Linda strain MAP in a viable culture.  The pelleted bacteria was then 
resuspended in 20 ml of M7H( w/ OADC and glycerol) with additional 1% 
glycine added.  The solution was incubated for 3 days at 37ºC.   A saline wash 
followed with a subsequent treatment in a CWD solution that includes 1.2% 
glycine, 30µL/ml lysozyme, 60% M7H9 w OADC, 40% 0.5M sucrose and 20mM 
MgCl2.  The bacteria were placed in the chemical bath for an eight day incubation 
period.  Post-incubation the CWD forms of MAP had to be examined quickly as 
gross reversions to normal MAP can occur in as little as 8 days when treated 




 Several different strains of dried Saccharomyces cerevisiae were obtained 
from a local brewer’s store and placed in nutrient broth for overnight culture.  
Additionally an official strain of S. cerevisiae purchased from the ATCC© 
(47058) was cultured in a same manner.  Since yeasts are facultative anaerobes, 
both aerobic and anaerobic culture conditions were applied and tested. A Candida 
albicans culture was obtained from Dr. Pamela Small, a Professor in 




Escherichia coli was purchased from ATCC© (23258 ) and cultured 
overnight in nutrient broth.  This strain was isolated from the urine of a human 
patient.   Streptococcus faecalis (ATCC© 19433) was cultured anaerobically 
overnight in brain heart infusion broth. Streptococcus gallolyticus (ATCC© 9809) 
was cultured in trypticase soy broth with defibrinated sheep blood under aerobic 
conditions.   A human isolate of Salmonella typhimurium (ATCC© 1311) was 
cultured aerobically in nutrient broth.  Yersinia enterocolitica (ATCC© 23715) 
was grown aerobically in tryptose broth.  Clostridium difficile (ATCC© 43600) 
isolated from the feces of a patient with colitis was cultured in reinforced 
Clostridial broth in anaerobic conditions.  Campylobacter jejejuni subsp. jejuni 
(ATCC© 33291) isolated from human feces was cultured in brucella broth with 
0.16% agar in aerobic conditions.  A human isolate of Listeria monocytogenes 
(ATCC© 19115) was cultured in brain heart infusion broth in aerobic conditions.  
A human isolate of Yersinia pseudotuberculosis (ATCC© 29910) was cultured in 
nutrient broth in aerobic conditions.  All cultures were checked for their 
opaqueness (indicating growth) and examined under light microscopy to affirm 
bacterial presence post-inoculation.   
  
The FCM Procedure 
 
Microorganisms harvested from liquid cultures were centrifuged to pellet 
the organisms.  The pellet was resuspended in Buffer A (PBS, 10% SuperBlock, 
0.05% Tween) at a 1:1 ratio of the initial culture volume extracted.    Using a 
Nunc® 96-well microarray plate which had a conical wells for centrifugation 
steps (Rochester, NY), 2µL of room temperature serum were introduced into the 
each well.  Pooled positive sera from JD+ farms and pooled negative sera from 
JD- farms were used as positive and negative controls, respectively.  Fetal Bovine 
Serum (FBS) was also used as a negative control.  Two wells were left completely 
devoid of any serum to examine the level of non-specific (background) binding of 
secondary antibody to the bacteria.  All sera and controls were tested in duplicate 
to ensure quality control.  Next, 100µL of suspension was inoculated into each 
well of a 96-well plate for a final serum-to-bacteria ratio of 1:50.   The solution 
was resuspended for proper mixing with the individual sera.  The plate was then 
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covered and placed upon a plate rocker for 1 hour to incubate.  After the 
incubation, each well was washed with Buffer A to remove any non-specific 
antibody binding to the whole-cell bacteria.  The washing steps consisted of three 
principle parts.  First, the plates were centrifuged at 3500 rpm and 20ºC for 10 
minutes.  This was done to move the heavier and stickier materials (the bacteria 
and bound antibodies to the bottom of the well where they became pellet).  Next, 
we removed the supernatant using a suction apparatus.  The remaining pellet was 
resuspended in Buffer A.  This procedure was repeated a second time to ensure 
the proper removal of any unwanted, non-specific antibodies that may have been 
left in the wells.   A final centrifugation and suction step was completed to 
prepare the samples for FITC tagging. 
Following the washes, a secondary antibody (2’ Ab) was added to tag the 
remaining bound antibody-bacterial complexes.  Since it has been shown that 
yeast can be a marker of disease when detecting both IgG and IgA, both 
antibodies were probed for in many of the assays  [20].  The FITC-labeled 2’ Ab 
(Jackson Immunology, West Grove, PA) was diluted to 1:25 using Buffer A. The 
96-well plates were covered with aluminum foil to prevent premature 
photoexcitation of FITC during the second incubation period.  Secondary 
antibody reactions were carried out at room temperature for 1 hour on a rocker.  
The complex was then diluted in 1 ml of PBS and run on the flow cytometer (LSR 
II, BD bioscience, San Diego, CA).  Detector voltages were set at 691 V for the 
Forward Scatter detector, 307 V for the Side Scatter, and 550 V for the FITC 
fluorescence detector.  The side scatter threshold was set at 200 V one that has 
been shown to preferentially select bacterium from surrounding materials.  
Measurements were conducted over a cell count of 10,000 units.  FITC 
fluorescent intensity was recorded as a measure of antibody presence.  This could 
be visualized by the histogram recorded by the FCM software.  A statistical 
analysis of the histogram was also included.   An example of one flow cytometry 
histogram and complimentary analysis recorded during an assay designed to 




The CD and HC serological groups were compared by ANOVA using a 
completely randomized design (SAS 2001).  If the serological groups were found 
to be significantly different with an α<0.05 then sensitivity and specificities were 
calculated using fixed cut-off values.  Cut-off values were estimated using the HC 
serum values:  the cut-off was defined as the mean of this HC population plus two 
standard deviations. Points lying above the cut-off values within the CD-free 
serum group were considered false positives. Specificity was calculated as (n false 
positive / n all negatives) x 100%.   Sera from the CD group that fell below the 
cut-off were considered false negatives. Sensitivity was calculated as (n tested 
positive / n all positives) x 100%.  Occasionally, gender was analyzed in a similar 
manner to that of disease-state to determine whether there were any differences in 























 Figure 11:  Example of the histogram and 















Antibody (IgG and IgA) binding to MAP was observed in CD and HC 
groups, whereas MAP (Linda Strain) treated only with 2’ Ab for IgG and IgA 
(Figure 12 and 13) showed no preferential binding for either serum population 
(both p>0.05).  This was true for the Linda strain, and also for several other MAP 
strains that we evaluated (data not shown).  Further, absorbtion with another 
related bacteria, M. phlei (which is commonly used to reduce antibody cross-
reactivity to other mycobacterium antigens in ELISA tests for CD), failed to 






























































Crohn’s Diseased Healthy Controls
Analysis of MAP using a IgG human antibody probe.  There were no 









































































Crohn’s Diseased Healthy Controls
Analysis of MAP using an IgA human antibody probe.   There were no 



























The CWD form of MAP prepared in this study seemed to resemble the 
spheroplasts’ rounder and slightly larger morphology described by Hines et al. 
when observed under a light microscope [83].  Yet in our pilot experiments, the 
spheroplasts failed to bind any antibody in either serum population.   
 
OtherBacteria   
 
  
 Non-MAP Suspects 
 
C. difficile, E. coli, C. jejuni, and S. faecalis all reacted strongly with 
antibodies in the sera of both the HC and CD groups.  Of these, C. difficile 
resulted in the greatest level of antibody binding -- as indicated by the fluorescent 
intensities that reached as high as 40,000 (unitless).  However, while it appears 
that these four bacteria showed some antibody binding, a differentiation of the 
two sera groups was not possible using FCM (p>0.05).  Our pilot studies with E. 
coli and S. faecalis led us to evaluate the two bacteria in separate all-sera studies.  
The results are shown in Figures 14 & 15.   
Many of the non-MAP bacteria that we surveyed produced a very low 
level of antibody binding.  Non-MAP bacteria with little to no antibody response 
included: L. monocytogenes, Y. entercolitica, and S. enterica.    In these cases, the 
bacteria in question failed to achieve fluorescence appreciably larger than that of 




S. cerevisiae differentiated the CD and HC sera groups with both IgG and 
IgA (Figures 16 & 17; both p<0.05).   Overall reactivity seemed to be higher in 
those within the IgG assay, with FITC values with a mean FITC value of 25,449 
within the CD group.  The HC group in the IgG assay had a mean FITC 
fluorescent value of 15,123.  FCM analysis using IgA was the more successful of 
the two assays.  
 
 
Human Sera IgG binding to E. coli


























Analysis of E. coli using a IgG human antibody probe.  There were no 














































































Analysis of E. faecalis using a IgGhuman antibody probe.  Ther
















































































Analysis of Baker’s yeast using an IgG human antibody probe.  Serum groups were significantly different (p<0.05).  CD 
mean = 25,449.  HC mean = 15,123.  At a CD cut-off of 33,151 sensitivity was 11/37 x 100% = 29.7% and specificity 
was ((1-(1/37) x100% ) =  97.3%.










































































































Crohn’s Diseased Healthy Controls
Human Sera IgA binding to S. cerevisiae
Analysis of Baker’s yeast using a IgA human antibody probe.  CD and HC groups significantly different (p<0.05).  CD 
mean =4,325.  HC mean =2,076. At a CD cut-off of  3,558 sensitivity was 13/37 x 100% = 35.1%.  Specificity was 





















sensitivity of 35.1%.  This assay’s specificity was accurate to 95% (35/37).  While 
the IgG assay had a better specificity of 97.3% (36/37 HC controls were true 
negatives), the tests’ sensitivity of 29.7% was slightly lower than that of its 
counterpart. Further testing using 11 different strains of S. cerevisiae under both 
aerobic and anaerobic conditions were unable to improve upon diagnostic 
sensitivity (data not shown). 
C. albicans w/ IgA (Figure 18) also differentiated the CD and HC sera 
groups (p<0.05).  There was significantly high reactivity within the CD group 
with FITC values as high as 100,000.  The FITC mean amongst the CD group was 
30,939.  The HC group had a mean FITC value of 16,878.  Sensitivities for the C. 
albicans FCM test was 24.1% (9/37 CD sera tested positive using our cut-off 
value).  This was the lowest of the FCM methods which were able to differentiate 
serum populations.  Specificity for this assay was 91.9% as 3 false negatives were 
detected.  In addition, there were no differences between gender as a 
subpopulation of the disease groups (p>0.05).   

























Crohn’s Diseased Healthy Controls
Analysis of C. albicans using a IgA human antibody probe.   CD and HC groups determined to 
be significantly different (p<.05).  CD mean determined to be 30,939.  HC group mean found to 
be 16,878. CD cut-off value determined to be at 49,486. Using this value sensitivity determined 
to be 9/37 x 100% or 24.3%.  Specificity was much lower than with IgG and determined to be 














































CHAPTER V: Discussion 
 
 
Summary of Results 
 
The results of this study are summarized in Figure 19.  While MAP were 
unable to differentiate the CD and HC groups under various experimental 
conditions, there were some encouraging aspects from our FCM studies using CD 
and HC sera.  Our study confirmed previous data obtained by many researchers 
which showed a higher overall antibody reactivity to S. cerevisiae for CD subjects 
when compared to healthy individuals.    While our sensitivities were not as high 
as some that have been reported, they approached those reported by Bossuyt in his 
review of  antibody markers of CD [21]. Similarly, C. albicans was able to 
differentiate the sera populations supporting the common antigen association 
discussed by Standaert-Vitse et al. [23].  
Many bacteria reacted strongly, but did not elicit sufficient differentiation 
to justify a full-length test.  Lastly, many of the bacteria failed to elicit any 
antibody binding whatsoever.  
  
Discussion of MAP Non-differentiation 
 
While there was certainly reactivity to MAPin our FCM, our MAP assays 
did not allow for differentiation of the two sera groups.  Few serological tests 
probing for MAP antibodies have been applied to CD populations, but one large 
population study by Bernstein et al. [34] revealed similar results our own..  Their 
study used 283 CD sera, 144 UC sera, and 402 HC sera to look for antibodies to 
MAP using a commercially available ELISA (IDEXX, Westbrook, ME) which 
had been manufactured for use in dairy cattle tests, but had been validated for 
human use as well.  Its validation in humans may come into question, though, as 
the positive control came from the pooled sera of a man who had accidentally 
inoculated himself with a killed MAP vaccine and had incurred a gramulatous 
legion at the injury site.  Negative controls of well-studied American Cross 
subjects who had no history of HC made up their control negative population to 
allow them to obtain S/P ratios.  A final strength of their study was that it used 
CD and HC volunteers from Manitoba, Candida; a region with a very high CD 
rate that coincides with high rate of MAP prevalence within the dairy cattle of the 
agricultural town [33].   
While there was a high rate of sera in Bernstein’s study which were 
considered positive, these sera were spread across all sera groups with an 
approximate overall seropositivity of 35%.  The authors found no true statistical 
difference between the two populations.  To be exact the CD sera were 37.8% 
positive while the HC group was 33.6% positive.  Further, gender was unable to 




































to MAP exposure that theauthors surveyed as MAP antibody-positive indicators.   
Unlike Bernstein et al., we lacked a true positive control to set cut-off 
values for the MAP FCM.  Thus we cannot properly estimate the sensitivity and 
specificity of our test.  Yet, like the authors, we were also unable to detect a 
antibody difference between the sera populations.  Either we do not have the 
correct antigen on our bacteria to elicit a differentiating response, or else MAP is 
sufficiently common bacteria for both HC and CD subjects to have built-up some 
antibody defense for it.  In addition, the preabsorbtion experiments with M. phlei 
were conducted to reduce potential cross-reactivity to other mycobacteria, but 
perhaps another future experiment could be designed using preabsorbtion with 
other mycobacterium.   Two promising candidates would be be M. kansassi and 
M. tuberculosis.  Thayer et. al found many MAP seropositive CD subjects to also 
be seropositive for these two mycobacteria [85].  Surprisingly, they found that 
100% of CD subjects that were seropositive to MAP were also seropositive to M. 
tuberculosis.  In addition, 43% of CD subjects seropositive to MAP, were also 
seropositive for M. kansassi.   
The genetic susceptibility of certain patients to CD suggests that MAP 
may need a G.I. system malfunction in order to invade and cause disease [5].  
Presently, we lack the proper genetic information on our subjects to explore this 
issue further.  Other important information we lack is the disease history of the 
CD subjects and their past treatment.  These data might help to explain if there 
has been a sufficient period of time for the subjects to develop a strong immune 
response, or, in some cases, if disease has been ongoing for too long, so that 
response has declined.  This latter possibility is highlighted in a study conducted 
by Olsen et al. in 2001 that compared the antibody titers to a MAP derived protein 
in subjects with CD and UC  [86].  While the CD subjects seemed to have an 
overall higher antibody response to the MAP proteins, a peculiar thing had 
occurred.  It seemed that the longer the period had been since each CD subject 
had been diagnosed with disease, the lower the antibody responses tended to be. 
This negative correlation was very strong: rs= -0.85 [86].  
A second patient history consideration we must take into account is what 
type of treatment has been administered.  For example it would have been useful 
to know whether or not immunosuppressant therapy and possibly even 
antimycobacterial medication had been administered to the CD patients.  
Immunosuppressant would lower the entire immune system, including humoral 
immunity. Although this treatment is usually reserved for subjects with severe CD 
who don’t respond to other treatments [4], we cannot rule out the possibility that 
our subjects were on immunosuppresants.  
 Our findings provide no affirmation of MAP’s possible role in CD 
via serological means, it would be premature to conclude that the mycobacterium 
is not involved in any manner.  Serological tests merely detect antibodies and thus 
are considered an ‘indirect’ means of determining causation.  Their presence, 
even in high titers, does not directly imply active, ongoing infection.  Our bodies 
possess memory B-cells which continually produce antibodies to specific antigens 
long after the body has cleared those antigens.   
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As previously discussed, much of the literature describing actual MAP  
within CD tissue has involved a CWD form  [1].  Thus using assays designed to 
detect antibodies against surface antigens of an intact bacteria (with an outer cell 
wall) may be unlikely to produce a successful differentiation.  Further, while we 
did attempt to test for reactions to spheroplastic forms of MAP, it cannot be 
assumed that this spheroplastic form is identical to that observed in vivo.  As 
Beran et al. note in their review of spheroplastic mycobacteria, no study has been 
produced which reveals the in vivo behavior of these chemically-formed CWD 
MAP  [87].  Thus, further research is needed to better verify the in vivo behavior 
exhibited chemically-induced spheroplastic so as to determine whether or not 
treated bacteria are sufficient for this sort of assay.  Secondly, spheroplastic 
bacteria may lack the necessary antigens to induce an immune response in the 
first place.  To date, no study has directly investigated the antibody-inducing 
ability of spheroplastic MAP.  However,  an extremely indirect evaluation of the 
spheroplastic antibody induction ability was conducted in a very recent study 
conducted by Hines et al. [88].  In this study the authors attempted to look for 
antibodies to chemically-induced spheroplastic MAP vaccines in goat kids.  The 
MAP bacteria were treated in a similar manner to our experiments to induce the 
spheroplastic form.  The bacteria were then killed and injected into the animals to 
evaluate vaccine effectiveness.   The researchers utilized a commercial Parachek 
® ELISA kit (Prionics, Zurich, Netherlands) to evaluate antibody responsiveness 
pre and post-challenge with live whole-cell pelleted MAP.   It is important to note 
that this ELISA uses antigens removed by a 30 minute sonication.  This step is 
likely to remove all antigens, even the most basal ones which a CWD MAP might 
possess.   In their study, none of the CWD vaccines were able to induce an 
appreciable humoral immune response.   
The water is further clouded by numerous reports of serological data that 
conflict with MAP DNA probe data.  This suggests that there is a disconnect 
between MAP presence within an individual, and the antibodies to that bacterium 
that have been stockpiled by that person’s humoral immune response.  This can be 
evidenced by a study conducted by Collins et al. in which used 2 separate 
diagnostic tests, that of PCR and that of the IDEXX©  ELISA [89].  A subset of 
their studies included a group of 181 individuals which consisted of HC, CD, and 
UC subjects.  Of these 36 were positive for MAP IS900 PCR.  Another 11 were 
positive for MAP antibodies by ELISA.  However, in not a single instance was a 
subject positive for both tests.    
 Lastly, the possibility exists that there is a strain of MAP which is 
more infectious than others.  If this was the case, it may elicit an entirely different 
antibody response than those for the non-infectious MAP.  Thus, while we may be 
detecting an antibody response in both HC and CD subjects, antibodies to the 
more infectious strain may have differentiated the populations.  Different strains 
of MAP may express unique surface antigens which have a complimentary set of 
antibodies predominantly present in those with CD.   This has been shown to be 
the case with other bacteria such as Helicobacter pylori which had differential 
antibody responses depending on strain type [90]. 
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 Antibody Reactions in Non-MAP Bacteria 
 
Of the non-MAP bacteria surveyed, 4 out of 9 had an appreciable antibody 
response across all sera groups.  One of the 4 non-reactive bacteria, S. 
gallolyticus, simply failed to grow.  The remaining three that failed to react may 
have behaved this way because these are bacteria that are less common and thus 
haven’t elicited a corresponding humoral immune response for those individuals 
tested.   For example,  L. monocytogenes -- a gram-positive bacteria that can 
survive refrigeration temperatures -- is more known for its role in a small 
percentage of food poisoning cases than as a commensal human gut microbe [38].  
Another, S. enterica subsp. typhimurium, is also being monitored carefully by the 
CDC, even though it is considered to be part of the normal natural flora of the 
human gut.  Of the remaining 5 that did react, none were able to differentiate the 
sera populations (p>0.05).   High environmental exposure rate to these microbes 
may have resulted in a generalized, high antibody titer that is common to both the 
HC and CD groups.   
 
 Differentiating Populations Using Whole-cell Yeast FCM 
 
Both of the yeast species that we used to investigate for unique antibody 
responses were able to differentiate the CD and HC populations.   Antibodies to S. 
cerevisiae were much more acute in their differentiating achieving overall assay 
sensitivities of 29.7% and 35.1% for IgG and IgA responses, respectively.  While 
one could look at the IgG responses and presume the two-fold higher FITC levels 
to be indicative of different antibody levels to MAP according to immunoglobulin 
type, this is not a safe assumption.   
The finding that the yeasts were able to differentiate the two sera groups is 
important because it proves that FCM can be a valuable means of detecting 
differential antibody responses.  It affirms studies by our lab, and by others, that 
the flow cytometer is sensitive enough to detect minute microbe-antibody 
complexes  [2, 80].   In 2006, Reese et al. conducted a rigorous metaanalysis on 
articles concerning serological markers within CD that included sifting through 
hundreds of articles to obtain the highest quality studies on ASCA and pANCA 
markers as predictors of disease  [91].  Sixty studies were choosen for a detailed 
statistical analysis.   None of the articles dealt with differentiating CD from HC 
populations, as the test is more commonly used to test CD from UC subjects.   
One subgroup of articles compared IBD versus non-IBD groups using 
ASCA IgA ELISAs, with an overall sensitivity of 31.4% obtained from a test 
population of 1,651 subjects.  This was very similar to the 35.1% sensitivity we 
achieved  when differentiating CD from HC groups using 74 subjects.   A review 
article detailing ASCA sensitivity and specificity information show our data to be 
consistent with many of the lower-end sensitivity estimates  (ranging from 40-
70%).  [21].  If sensitivity for ASCAs could be improved for the FCM, 
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technological advances in microfluidic flow cytometers would allow for quicker, 
in-house tests to be conducted.   
 Antibodies to C. albicans were less apt to separate the sera 
populations.  These were the lowest assay sensitivities achieved by detecting only 
9 of the 37 or 24.3% of the CD sera as positive.  There are four common cell wall 
macromolecules shared between S. cerevisiae and C. albicans [92].  These consist 
of chitin, mannoproteins, β(1,6) glucan, and , β(1,3) glucan. Since these cell wall 
constituents are expressed on the outer surface of both yeasts (albeit in different 
concentrations), antibodies directed towards the entities are likely to cause a 
cross-reactivity event.  That is, antibodies directed towards the cell wall of S. 
cerevisiae are also binding to that of C. albicans.  As stated previously, this has 
been proven as C. albicans has been shown to cause false positive results in the 
ASCA test  [23]. 
  
 Final Thoughts 
 
The experiments reported here represent a first attempt to utilize FCM to 
improve CD diagnostics.  Our previous success with the method in an animal 
model made this attempt to apply FCM to human sera the logical next step.  
Given our present lack of success, it is clear that the problem is not a simple one, 
but it certainly seems worth continuing to pursue.  Meanwhile, CD continues in 
its enigmatic ways among the human population.  There are those who feel that 
the disease is strictly a bacterial issue and others who feel another mechanism 
may be at the center of the cause – given the present state of knowledge, we 
suggest the answer probably lies somewhere in between .   
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